Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis.
Ze MiYunshu ZhangZhichao FengJiahao LiuJianmin WuHongpei TanXiaoqian MaZhen-Guo LiuPengfei RongPublished in: Artificial cells, nanomedicine, and biotechnology (2022)
PD-L1 inhibitors plus CTLA-4 inhibitors shows better safety in treatment-related adverse events than PD-1 inhibitors plus CTLA-4 inhibitors.
Keyphrases